The CHMP renders a positive opinion recommending approval for MRK's Keytruda for the first-line treatment of malignant ...
Cancer is on the rise in America - especially among younger adults. Learn about what lifestyle choices may help to avoid early-onset cancer.
4h
Actively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage bio ...
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
Actively Exploring Partnership for Alzheimer’s DevelopmentSupplementary Financing Concluded in Q4ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE ...
At age 20, while studying sports management and marketing in college, Sean Kukoleck's life was disrupted by cancer. He suffered his first-ever seizure, leading to the discovery of a large mass on ...
Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...
Merck (MRK) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion ...
The U.S. Food and Drug Administration approved the Keytruda combination in malignant pleural mesothelioma in September. Keytruda, a cancer drug that harnesses a patient's immune system to fight tumors ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
Vibostolimab/Keytruda regimen did not improve overall survival compared to Tecentriq in extensive-stage SCLC patients. Median ...
Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback